Answers are grounded in this paper and cite their sources.
Parkinson's disease (PD) diagnosis remains a substantial clinical challenge due to its heterogeneous symptomatology and the absence of reliable early-stage biomarkers. While molecular imaging offers promise, current methods are lengthy or have limited specificity. Here, we combined a rapid molecular MRI acquisition paradigm with deep learning based reconstruction for multi-metabolite quantification of glutamate, mobile proteins, semisolid, and mobile macromolecules in an acute MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model. The resulting quantitative parameter maps align well with histology and magnetic resonance spectroscopy (MRS) findings. Notably, the semisolid magnetization transfer (MT), amide, and aliphatic relayed nuclear Overhauser effect (rNOE) proton volume fractions emerged as promising PD biomarkers.
No takes yet. Share an insight, caveat, or question.
Shmuely et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: